Biovica Biovica is a biotech company that develops and commercializes blood-based biomarker assays that help to monitor cancer therapies and predict patient outcomes. | ![]() Biocept Biocept employs cell separation technology to develop a class of diagnostic assays for the early detection and diagnosis of cancer. | Universal Diagnostics Universal Diagnostics (UDX) is a bioinformatics, multi-omics, and in-vitro diagnostics company that develops minimally invasive and blood-based solutions for detecting cancer. | ||
Founding Date | Founding Date 2009 | Founding Date 1997 | Founding Date 1993 | Founding Date 2012 |
Type | Type Public | Type Private | Type Public | Type Private |
Tags | ||||
Locations | Locations Uppsala, SE HQ Waltham, US | Locations Alpharetta, US HQ | Locations San Diego, US HQ | Locations Seville, ES HQ Ljubljana, SI Madrid, ES Cambridge, US |
Employees | Employees 26 | Employees 1543% increase | Employees 878% decrease | Employees 1271% increase |
Valuation ($) | Valuation ($) 20.5 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A |
Financial | ||||
Revenue (est.) | Revenue (est.) kr13.4m (FY, 2026) | Revenue (est.) N/A | Revenue (est.) $25.9m (FY, 2022) | Revenue (est.) N/A |
Cost of goods | Cost of goods kr43k (FY, 2026) | Cost of goods N/A | Cost of goods $28.4m (FY, 2022) | Cost of goods N/A |
Gross profit | Gross profit kr14m (FY, 2026) | Gross profit N/A | Gross profit ($2.5m) (FY, 2022) | Gross profit N/A |
Net income | Net income (kr69.9m) (FY, 2026) | Net income N/A | Net income ($32.1m) (FY, 2022) | Net income N/A |

CSI Laboratories is a cancer testing and diagnostics laboratory.
View company
Biocept employs cell separation technology to develop a class of diagnostic assays for the early detection and diagnosis of cancer.
View companyUniversal Diagnostics (UDX) is a bioinformatics, multi-omics, and in-vitro diagnostics company that develops minimally invasive and blood-based solutions for detecting cancer.
View company